Korea United Pharm

033270 · KOSPI

Public Market Listing

033270KOSPI

KOSPI primary exchange listing

Live quotes, historical charts, and market capitalization for Korea United Pharm are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
PDE3 (phosphodiesterase 3) and HMG-CoA reductaseSmall molecule
Atherosclerotic Cardiovascular Disease
UIC201604No recent activity
Phase 1
HMG-CoA reductaseSmall molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$50M———report ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$203M———report ↗

Korea United Pharm reported revenue of $203.24M, down 4.2% YoY for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$212M———report ↗